Bradley McGregor, MD

Articles

Dr McGregor on the Potential Use of Checkpoint Inhibitors in Rare GU Cancers

January 20th 2025

Bradley McGregor, MD, discusses the rationale for investigating nivolumab plus ipilimumab in advanced, rare genitourinary malignancies.

Dr McGregor on the Updated NCCN Guidelines for Non–Clear Cell RCC

September 6th 2024

Bradley McGregor, MD, discusses the current NCCN guideline recommendations for the treatment of patients with divergent RCC histologies.

Dr McGregor on the Investigation of Abemaciclib Monotherapy in ccRCC

August 28th 2024

Bradley McGregor, MD, discusses the rationale for investigating abemaciclib monotherapy in patients with clear cell renal cell carcinoma.

Dr McGregor on Challenges and Future Research Directions in ccRCC

August 22nd 2024

Bradley McGregor, MD, discusses ongoing treatment challenges and future research directions in clear cell renal cell carcinoma.

Dr McGregor on the Future Implications of Ongoing Research in RCC

August 21st 2024

Bradley McGregor, MD, discusses the future implications of evolutions in the renal cell carcinoma treatment paradigm.

Dr McGregor on the Data for Abemaciclib in Advanced ccRCC

July 12th 2024

Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib in clear cell renal cell carcinoma.

Dr McGregor on the Rationale for the DAD Trial in Metastatic Urothelial Cancer

June 4th 2024

Bradley McGregor, MD, discusses the investigation of sacituzumab govitecan plus enfortumab vedotin in metastatic urothelial cancer.

Dr McGregor on the DAD-IO Trial in Treatment-Naive Metastatic Urothelial Carcinoma

June 4th 2024

Bradley McGregor, MD, discusses the DAD-IO trial of sacituzumab govitecan, enfortumab vedotin, and pembrolizumab in metastatic urothelial cancer.

Dr McGregor on Sacituzumab Govitecan Plus Enfortumab Vedotin in Treatment-Resistant mUC

February 5th 2024

Bradley McGregor, MD, discusses the next steps for investigating cabozantinib plus atezolizumab in patients with advanced renal cell carcinoma.

Dr McGregor on Next Steps For Cabozantinib Plus Atezolizumab in Advanced RCC

April 14th 2023

Bradley McGregor, MD, discusses the next steps for investigating cabozantinib plus atezolizumab in patients with advanced renal cell carcinoma.

Dr. McGregor on Cabozantinib Plus Atezolizumab in Non–Clear Cell RCC

February 20th 2023

Bradley McGregor, MD, discusses the investigation of cabozantinib plus atezolizumab in patients with non–clear cell renal cell carcinoma.

Dr. McGregor on Belzutifan Plus Lenvatinib in Advanced RCC

November 4th 2022

Bradley McGregor, MD, discusses the rationale behind combining belzutifan with lenvatinib in pretreated patients with advanced renal cell carcinoma with clear cell components.

Latest in Lung, Genitourinary, Gynecologic, and Breast Cancers From ASCO 2022: Drs Charu Aggarwal, Bradley McGregor, Robert Coleman, and Kevin Kalinsky

June 7th 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Advanced Bladder Cancer: Adopting Newer Therapies into Clinical Practice

February 3rd 2022

Bradley McGregor, MD, reacts to treatment advances for advanced bladder cancer and shares perspective on utilizing newer, novel therapies as the field continues to evolve

Dr. McGregor the Potential Utility of Cabozantinib/Nivolumab in Advanced RCC

November 7th 2020

Bradley McGregor, MD, discusses the potential utility of the combination of cabozantinib and nivolumab in advanced renal cell carcinoma (RCC).

Dr. McGregor on the Need to Develop Novel Targets in RCC

September 8th 2020

Bradley McGregor, MD, discusses the need to develop novel, actionable targets in renal cell carcinoma.

Dr. McGregor on Combos With Nivolumab, Cabozantinib, and Sunitinib in RCC

February 29th 2020

Bradley McGregor, MD, discusses combination therapies with nivolumab, cabozantinib, and sunitinib in renal cell carcinoma.

Dr. McGregor on Unmet Needs in Non-Clear Cell RCC

October 21st 2019

Bradley McGregor, MD, discusses the challenges of developing treatment strategies for patients with non-cell clear renal cell carcinoma.

Dr. McGregor on Choosing Combo Regimens in Advanced RCC

September 16th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses how to choose between combination treatments in advanced renal cell carcinoma.

Dr. McGregor on Unmet Needs in Advanced RCC

July 17th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses unmet needs in advanced renal cell carcinoma (RCC).